240 related articles for article (PubMed ID: 23713567)
1. Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
Purushottamachar P; Godbole AM; Gediya LK; Martin MS; Vasaitis TS; Kwegyir-Afful AK; Ramalingam S; Ates-Alagoz Z; Njar VC
J Med Chem; 2013 Jun; 56(12):4880-98. PubMed ID: 23713567
[TBL] [Abstract][Full Text] [Related]
2. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
Vasaitis T; Belosay A; Schayowitz A; Khandelwal A; Chopra P; Gediya LK; Guo Z; Fang HB; Njar VC; Brodie AM
Mol Cancer Ther; 2008 Aug; 7(8):2348-57. PubMed ID: 18723482
[TBL] [Abstract][Full Text] [Related]
4. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
Njar VC; Brodie AM
J Med Chem; 2015 Mar; 58(5):2077-87. PubMed ID: 25591066
[TBL] [Abstract][Full Text] [Related]
5. Salinization Dramatically Enhance the Anti-Prostate Cancer Efficacies of AR/AR-V7 and Mnk1/2 Molecular Glue Degraders, Galeterone and VNPP433-3β Which Outperform Docetaxel and Enzalutamide in CRPC CWR22Rv1 Xenograft Mouse Model.
Thankan RS; Thomas E; Purushottamachar P; Weber DJ; Njar VCO
Bioorg Chem; 2023 Oct; 139():106700. PubMed ID: 37392559
[TBL] [Abstract][Full Text] [Related]
6. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.
Yu Z; Cai C; Gao S; Simon NI; Shen HC; Balk SP
Clin Cancer Res; 2014 Aug; 20(15):4075-85. PubMed ID: 24874833
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
Jorda R; Řezníčková E; Kiełczewska U; Maj J; Morzycki JW; Siergiejczyk L; Bazgier V; Berka K; Rárová L; Wojtkielewicz A
Eur J Med Chem; 2019 Oct; 179():483-492. PubMed ID: 31271960
[TBL] [Abstract][Full Text] [Related]
8. Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities.
Alyamani M; Li Z; Berk M; Li J; Tang J; Upadhyay S; Auchus RJ; Sharifi N
Cell Chem Biol; 2017 Jul; 24(7):825-832.e6. PubMed ID: 28648378
[TBL] [Abstract][Full Text] [Related]
9. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.
Bruno RD; Vasaitis TS; Gediya LK; Purushottamachar P; Godbole AM; Ates-Alagoz Z; Brodie AM; Njar VC
Steroids; 2011 Nov; 76(12):1268-79. PubMed ID: 21729712
[TBL] [Abstract][Full Text] [Related]
11. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
Gianti E; Zauhar RJ
J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
[TBL] [Abstract][Full Text] [Related]
12. Large-scale synthesis of galeterone and lead next generation galeterone analog VNPP433-3β.
Purushottamachar P; Thomas E; Thankan RS; Rudchenko V; Huang G; Njar VCO
Steroids; 2022 Sep; 185():109062. PubMed ID: 35690119
[TBL] [Abstract][Full Text] [Related]
13. 17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.
Bruno RD; Gover TD; Burger AM; Brodie AM; Njar VC
Mol Cancer Ther; 2008 Sep; 7(9):2828-36. PubMed ID: 18790763
[TBL] [Abstract][Full Text] [Related]
14. Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.
Purushottamachar P; Kwegyir-Afful AK; Martin MS; Ramamurthy VP; Ramalingam S; Njar VC
ACS Med Chem Lett; 2016 Jul; 7(7):708-13. PubMed ID: 27437082
[TBL] [Abstract][Full Text] [Related]
15. Galeterone for the treatment of advanced prostate cancer: the evidence to date.
Bastos DA; Antonarakis ES
Drug Des Devel Ther; 2016; 10():2289-97. PubMed ID: 27486306
[TBL] [Abstract][Full Text] [Related]
16. New steroidal oxazolines, benzoxazoles and benzimidazoles related to abiraterone and galeterone.
Latysheva AS; Zolottsev VA; Veselovsky AV; Scherbakov KA; Morozevich GE; Pokrovsky VS; Novikov RA; Timofeev VP; Tkachev YV; Misharin AY
Steroids; 2020 Jan; 153():108534. PubMed ID: 31678134
[TBL] [Abstract][Full Text] [Related]
17. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
18. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.
Soifer HS; Souleimanian N; Wu S; Voskresenskiy AM; Collak FK; Cinar B; Stein CA
J Biol Chem; 2012 Feb; 287(6):3777-87. PubMed ID: 22174412
[TBL] [Abstract][Full Text] [Related]
19. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
20. Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer.
Montgomery B; Eisenberger MA; Rettig MB; Chu F; Pili R; Stephenson JJ; Vogelzang NJ; Koletsky AJ; Nordquist LT; Edenfield WJ; Mamlouk K; Ferrante KJ; Taplin ME
Clin Cancer Res; 2016 Mar; 22(6):1356-63. PubMed ID: 26527750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
